| RECOMMENDATION 16 |
| We recommend the use of lanadelumab as first-line long-term prophylaxis. |
| 89% agreement, (strong recommendation), evidence level A |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.